10-K/A: 23andMe Files Amended Annual Report Amid Nasdaq Delisting and Restructuring Efforts

23andMe Holding Co. filed an amended annual report to include executive compensation and corporate governance details, confirming its delisting from Nasdaq and ongoing Chapter 11 bankruptcy proceedings.

Summary

• The filing is an Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended March 31, 2025, primarily to include information on Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accounting Fees, which were omitted from the original filing.
• 23andMe Holding Co. was delisted from The Nasdaq Stock Market LLC, with trading suspended on March 31, 2025, and its Class A common stock began trading on the OTC Pink Market under the symbol MEHCQ.
• The company is undergoing voluntary Chapter 11 bankruptcy proceedings, with a Chief Restructuring Officer appointed to oversee the restructuring and sale process.
• Anne Wojcicki resigned as Chief Executive Officer effective March 23, 2025, but continues to serve as a Class III director.
• Joseph Selsavage was appointed Interim Chief Executive Officer and Chief Financial and Accounting Officer effective March 23, 2025.
• Matt Kvarda was appointed Chief Restructuring Officer effective March 23, 2025, with Alvarez & Marsal North America, LLC engaged for financial advisory services, including a $750,000 incentive compensation tied to the consummation of a Chapter 11 plan or sale of assets/equity.
• The Compensation Committee exercised its discretion to make no payouts under the Fiscal 2025 Annual Incentive Plan, despite achieving 25% of the target performance metrics (Gross Margin and Adjusted EBITDA).
• The aggregate market value of voting stock held by non-affiliates was approximately $120.3 million as of September 30, 2024, based on a Class A common stock price of $6.95 per share.
• As of July 17, 2025, there were 25,431,244 shares of Class A common stock and 2,110,250 shares of Class B common stock issued and outstanding.
• The ratio of combined CEO annual total compensation ($79,544) to the median employee's total compensation ($242,581) was approximately 3:1 for Fiscal 2025.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the Nasdaq delisting, initiation of Chapter 11 bankruptcy proceedings, significant financial losses, and the Compensation Committee's decision to withhold executive bonuses despite some performance targets being met. These factors indicate severe financial distress and operational challenges.

Positives

• The company has adopted a Compensation Recoupment Policy (Clawback Policy) in compliance with Nasdaq listing standards, providing for mandatory recoupment of erroneously awarded incentive-based compensation and discretionary recoupment for certain misconduct.
• The Board has appointed new independent directors with extensive experience in finance, technology, and restructuring, including a seasoned bankruptcy attorney, Thomas Walper.
• The company received strong stockholder support (99% of shares cast in favor) for its Fiscal 2024 named executive officer compensation in a Say-on-Pay vote.

Negatives

• The company's securities were delisted from Nasdaq and now trade on the OTC Pink Market, indicating a significant loss of market standing and liquidity.
• The company is undergoing voluntary Chapter 11 bankruptcy proceedings, signaling severe financial distress and potential restructuring of its operations and capital structure.
• The Compensation Committee determined that no payouts would be made under the Fiscal 2025 Annual Incentive Plan to any participating NEO, despite some performance achievement, reflecting a challenging financial year.
• Net Income (Loss) for Fiscal 2025 was $(280.89) million, indicating substantial financial losses.
• Company TSR for Fiscal 2025 was $0.28 based on an initial $100 investment, significantly underperforming the Peer Group TSR of $117.00.

Risks

• The ongoing Chapter 11 bankruptcy proceedings pose significant risks to the company's operations, financial stability, and future viability.
• Delisting from Nasdaq to the OTC Pink Market reduces liquidity and investor confidence, potentially impacting the company's ability to raise capital or attract new investors.
• The company's financial performance, including negative net income and low gross margin achievement, indicates ongoing operational challenges.
• The departure of key executives, including the former CEO and Head of Therapeutics Discovery, during a period of restructuring could impact strategic direction and operational continuity.
• The lack of correlation between executive compensation (CAP) and Net Income (Loss) or Gross Margin in prior fiscal years suggests potential misalignment of incentives with overall company profitability.

Future Outlook

The company is undergoing a restructuring and sale process, with the Chief Restructuring Officer leading efforts to identify and implement cost reduction and operational improvement opportunities. The A&M engagement includes incentive compensation payable upon the consummation of a Chapter 11 plan of reorganization or the sale, transfer, or other disposition of all or a substantial portion of the company's assets or equity.

Management Comments

• The company's ability to ensure executive officers are engaged and productive depends upon how the compensation program is structured.
• To be appropriately positioned to attract new talent, the company must be prepared to be, and be perceived as, an employer that offers competitive compensation.
• Providing executive officers an opportunity to be partial owners in the business fosters active engagement, strengthens retention objectives, and aligns long-term interests with stockholders.
• The Compensation Committee believes that the company's compensation programs are balanced and do not create risks reasonably likely to have a material adverse impact on the company.

Industry Context

The company's delisting and Chapter 11 proceedings highlight significant challenges within the direct-to-consumer DNA testing and therapeutics discovery sectors, which often face intense competition, regulatory scrutiny, and high R&D costs. The appointment of a Chief Restructuring Officer and a bankruptcy attorney to the board indicates a severe need for financial reorganization, a situation not uncommon for early-stage or rapidly evolving biotech companies that fail to achieve profitability or secure sufficient funding.

Comparison to Industry Standards

• The company's Total Shareholder Return (TSR) of $0.28 for Fiscal 2025 (based on an initial $100 investment from June 17, 2021) significantly underperformed the S&P 500 Healthcare Sector Index, which had a TSR of $117.00 for the same period.
• The company's Gross Margin of $100.3 million for Fiscal 2025 was below its minimum target of $110 million for the Annual Incentive Plan, indicating underperformance relative to internal goals.
• The company's Adjusted EBITDA of $(119.2 million) for Fiscal 2025 met the maximum achievement level for the Annual Incentive Plan, suggesting some success in managing operational expenses relative to internal targets, despite overall losses.

Management Changes

Corporate Governance

Legal Proceedings

• The company is undergoing voluntary Chapter 11 bankruptcy proceedings, which involve legal processes for financial reorganization and potential asset disposition.

Related Party Transactions

• The company recognized $19.7 million in revenue during Fiscal 2025 under the GSK Agreements, providing GSK plc (a 5% or Greater Holder) with a non-exclusive license to new de-identified, aggregated data and access to research services.
• The company recognized $0.7 million in revenue during Fiscal 2025 from the TWF Agreement with the Troper Wojcicki Foundation (TWF), a related party due to Anne Wojcicki's sibling's involvement, for research services related to lung cancer.
• The company paid Richard Scheller, a former director, $10,000 during Fiscal 2025 pursuant to a consulting agreement.

Stakeholder Impact

• Shareholders: Significant negative impact due to Nasdaq delisting, reduced liquidity, potential loss of value from Chapter 11 proceedings, and poor TSR performance.
• Employees: Uncertainty and potential job losses due to restructuring and bankruptcy proceedings, though some executives received retention bonuses.
• Creditors: Will be directly impacted by the Chapter 11 proceedings as the company seeks to reorganize its debts.
• Customers: Potential impact on service continuity or product development depending on the outcome of the restructuring and sale process.
• Suppliers: May face payment delays or renegotiated terms due to the bankruptcy proceedings.

Next Steps

• The company will continue with its voluntary Chapter 11 bankruptcy proceedings, overseen by the Chief Restructuring Officer.
• The Chief Restructuring Officer will assist in identifying and implementing cost reduction and operational improvement opportunities.
• The Chief Restructuring Officer will serve as the principal contact with the company's creditors regarding financial and operational matters.
• The company aims for the consummation of a Chapter 11 plan of reorganization or the sale, transfer, or other disposition of all or a substantial portion of its assets or equity.
• The company will continue to monitor its compensation policies and practices to ensure risk management objectives are met.
• The company's Class A common stock will continue to trade on the OTC Pink Market under the symbol MEHCQ.

Key Dates

Recommendation

The company's delisting from Nasdaq, initiation of voluntary Chapter 11 bankruptcy proceedings, and appointment of a Chief Restructuring Officer signal severe financial distress and a high probability of significant shareholder value erosion. The substantial underperformance against its peer group in TSR and the decision to withhold executive bonuses further underscore the dire situation. While restructuring aims to preserve value, existing equity holders typically face substantial dilution or complete loss of investment in such scenarios. A seasoned investor would likely seek to exit their position immediately.

Keywords

SEC filing, 10-K/A, Annual Report Amendment, Nasdaq delisting, OTC Pink Market, Chapter 11 bankruptcy, Restructuring, Executive compensation, Corporate governance, Financial performance, Gross Margin, Adjusted EBITDA, Shareholder value, Risk management, Biotechnology, Genetics, Direct-to-consumer DNA testing